compname reports quarterly earnings per share of $0.78, quarterly adjusted earnings per share of $0.64.
qtrly earnings per share $0.78; qtrly adjusted earnings per share was $0.64.
2021 sales guidance raised to $5.2 billion to $5.4 billion from $4.9 billion to $5.3 billion.
qtrly sales grew 49% to $1.4 billion; underlying sales grew 44%.
qtrly reported transcatheter aortic valve replacement sales of $902 million, up 52% on a reported basis.
projects q3 sales to be between $1.29 billion and $1.37 billion, adjusted earnings per share of $0.50 to $0.56.
edwards lifesciences sees fy underlying tavr sales growth of around 20% versus previous sales growth expectation of 15% to 20%.
recorded reduction in fair value of contingent liabilities in quarter, a $0.14 benefit that was excluded from adjusted eps.
raising fy 2021 adjusted earnings per share guidance to the high end of the previous $2.07 to $2.27 range.
